PROM1 and cancer: In corroboratory assays, we demonstrated that concomitantly with reduced tumorsphere size and quantity in the shMALAT1 cells, the immunoreactivity of the cancer-associated pluripotency marker CD133, and mesenchymal and/or liver stem cell marker CD90/THY-1 [19,20] was significantly suppressed in the shMALAT1 cells, compared to the scrambled control (Figure 5A).